Positive Phase II Bolsters Aura Bioscience's Confidence in VDC-based Therapy for Ocular ...
Aura Biosciences' new therapy, bel-sar, for early-stage choroidal melanoma shows promise in Phase II trials, potentially offering a vision-preserving alternative to radiation therapy. The treatment uses virus-drug conjugates activated by light to target tumors, with results indicating high efficacy and safety. Aura plans to advance to Phase III trials and explore broader cancer applications.
Related Clinical Trials
Reference News
Aura Biosciences announced positive Phase 2 results for bel-sar (AU-011) in treating early-stage choroidal melanoma, showing 80% tumor control and 90% visual acuity preservation with a favorable safety profile, presented at The Retina Society Annual Meeting in Lisbon.
Aura Biosciences announced positive phase 2 results for bel-sar (AU-011) in treating early-stage choroidal melanoma, showing 80% tumour control and 90% vision preservation with a favourable safety profile.
Aura Biosciences' new therapy, bel-sar, for early-stage choroidal melanoma shows promise in Phase II trials, potentially offering a vision-preserving alternative to radiation therapy. The treatment uses virus-drug conjugates activated by light to target tumors, with results indicating high efficacy and safety. Aura plans to advance to Phase III trials and explore broader cancer applications.